Mochida Pharmaceutical Co., Ltd. Overview
Pro stress-test →Mochida Pharmaceutical manufactures and sells pharmaceuticals and healthcare products in Japan. The company primarily develops new drugs for treating intractable diseases and generic drugs, with therapeutic focus on cardiology, obstetrics and gynecology, psychiatry, and gastroenterology. As a mid-cap Japanese pharmaceutical player, it has demonstrated improving profitability driven by operational efficiency gains.
Strategic Profile
Pro stress-test →In fiscal year 2026, the company reported revenue of ¥117.0 billion (up 11% from FY 2025) with net income of ¥7.90 billion (up 39% from FY 2025) and profit margin expansion to 6.8% from 5.4%. In September 2025, Mochida agreed to acquire a 20% stake in And Pharma Co., Ltd. for ¥16.2 billion, signaling strategic expansion into emerging biotech partnerships. The company maintains a balanced dividend policy while pursuing selective M&A to strengthen its therapeutic pipeline.
Competitive Landscape
Pro stress-test →Mochida competes in the Japanese pharmaceutical market dominated by larger integrated players (Takeda, Daiichi Sankyo, Eisai). Its strength lies in specialized therapeutic areas (gynecology, psychiatry, gastroenterology) and generic drug capabilities. The And Pharma partnership signals differentiation strategy toward regenerative medicine and niche therapeutic development rather than head-to-head competition with megacaps.
Industry Context
Mochida Pharmaceutical Co., Ltd. operates in Japanese specialty pharmaceuticals.
Key facts
Founded: 1913 · Headquarters: Shinjuku-ku, Tokyo, Japan · Employees: 1,479 · Revenue: ¥117.0 billion (FY 2026) · Market cap: ¥120.9-¥125.9 billion ($0.9-1.0B)